NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it has signed an agreement with Philadelphia based Numoda Capital Innovations, an investment arm of Numoda Corporation, pursuant to which Numoda Capital has agreed to become an investor in the Company which will be aimed at bringing faster, more cost effective clinical trials to the university level.
This collaboration would combine the innovative patented platforms and reporting engines of Numoda with the cutting edge proprietary technologies utilized by IntelliCell in separation of adipose tissue into stromal vascular fraction containing stem cells, to bring the advantage of these technologies to further promote vital university clinical development.
Presently, autologous stem cell research is focused on deriving these cells from bone marrow or adipose tissue. In the case of bone marrow, the cells need to be cultured to increase the number of cells to therapeutic numbers. This takes weeks to accomplish and is costly. With enzymatic separation, the enzymes are costly (over $1,000 per sample) and their use is controversial. Prior to the introduction of the proprietary, non-enzymatic extraction process utilized by IntelliCell, adipose derived stem cells were produced using enzymes to yield the stromal vascular fraction (SVF cells) that resides in the adipose tissue. Using either method, stem cell research is extremely costly and time consuming. IntelliCell’s non-enzymatic process allows a patient to be treated from start to finish in less than one hour. Dr. Steven Victor said “using only 60cc’s versus 200cc’s of adipose tissue that is required for the enzymatic process, in about 30 minutes, IntelliCell is able to generate between 0.5 billion and 1 billion SVF cells. A majority of the SVF cells are all the lineages of multipotent stem cells that exist in our body. Only sound and saline are used to manufacture what we believe to be the largest amount of autologous, stem cells produced in the shortest amount of time, and at 10-20% of the research costs required when using traditional enzymatic methods. This will dramatically increase the efficiency of the R&D dollars spent by any stem cell research center. We are extremely excited to be collaborating with Numoda Corporation to combine our breakthrough technology with their IT technology. Together major universities conducting stem cell research will be able to perform many more trials for the same amount of money.”
IntelliCell is a pioneering regenerative medicine. The stem cell research market is large and rapidly growing. Numoda’s Chairman, Mary Schaheen said “incredible research in stem cells is being done in at least 55 universities; this unique collaboration allows these research facilities to further their own pursuits through access to these exciting technologies.”
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.
Numoda Corporation is the innovative partner to the life science industry that has delivered the norms that have become a best practice for achieving improved clinical and strategic partnering outcomes, through a unique blend of leading clinical trial information and process management expertise, budget oversight, strategic partnering services, and specialized technologies. Numoda's best practices strengthen the business case for new therapies by ensuring efficient deployment of funds and rapidly reporting the highest quality of clinical data to facilitate earlier monetization events. Through an investment affiliate, Numoda also helps clients advance their medical research through direct investment and facilitating strategic partnerships. For additional information, visit http://www.numoda.com or call 215-238-8881.